Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: November 26, 2022

Details for Patent: 7,857,802

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,857,802
Title:Connector for medical liquid-containing packages and medical liquid-containing packages
Abstract: The invention relates to a connector for medical liquid-containing packages, in particular to infusion or transfusion bags comprising a connection element (1) provided with a channel-shaped opening (1c) in which a self-sealing membrane (8) is arranged. A breakable part (17) which is connected to the connection piece closes the channel-shaped opening. Above the membrane (8), said connection element is embodied in the form a connection piece (13) comprising an internal cone (14) and external thread (15), the membrane (8) being sealed for receiving a syringe cone shaft. The inventive connector makes it possible to inject an active substance by means of a conventional Luer lock syringe devoid of an injection cannula (needle).
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg V.D.H., DE)
Application Number:10/575,690
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,857,802
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,857,802

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 AP RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,857,802

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 48 016Oct 15, 2003
PCT Information
PCT FiledOctober 15, 2004PCT Application Number:PCT/EP2004/011603
PCT Publication Date:April 28, 2005PCT Publication Number: WO2005/037362

International Family Members for US Patent 7,857,802

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004281535 See Plans and Pricing
Brazil PI0415438 See Plans and Pricing
Canada 2542408 See Plans and Pricing
China 100577234 See Plans and Pricing
China 1867375 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.